brentuximab vedotin
takeda,seagen
['echelon-1']
much awaited os data of echelon-1 trial shows pfs advantage being translated into os benefit. outside efficacy, so heartening to see ~86% resolution of peripheral neuropathy in pts rx'ed w/ aavd, which is often the dose-limiting toxicity and long-term sequelae for pts #asco22 
Hematology-Oncology fellow @MountSinaiNYC????????? 
Interests: #lymsm, #mmsm, Cellular therapies
@nytimes https://t.co/ooNmeRfxJf